About

WHY EASL CREATED A FOUNDATION

For many years, the EASL Governing Board has heard from different partners and stakeholders about the need to extend the top level science and educational initiatives beyond Europe. EASL listened to the community and then analyzed the best way to respond in the most effective manner. Following independent advice, the need to establish a dedicated vehicle to support this objective was clearly identified and executed in order for EASL can to focus on its core activities derived from the latest scientific research and so that liver knowledge can be shared with everyone. In 2016, the EASL International Liver Foundation was established by EASL and Professor Massimo Colombo was appointed as the board chairperson.

 

The board

PROF. Massimo COLOMBO

Chairman

Massimo Colombo is Chairman of the EASL International Liver Foundation, Geneva, Switzerland. He is also Head of the Liver Center for Translational Research, IRCCS Humanitas, Milan, Italy. His research interests include the diagnosis and treatment of viral hepatitis, liver transplantation and liver cancer.
Read more.

Prof. Christian Bréchot

Board Member

Christian Bréchot has been the President of Institut Pasteur since October 1st, 2013. His research mainly focuses on viral hepatitis: hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer (Hepatocellular carcinoma: HCC) and to the molecular mechanisms that drive liver regeneration and cancer (in particular, cell cycle deregulation).  His research activities have led him to obtain 13 patents and to contribute to the creation of two biotech companies : Rarecells and ALFACT Innovation.
Read more.

Prof. Jordi BRUIX

Board Member

Jordi Bruix is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain. Prof. Bruix has been the principal investigator of studies and clinical trials that have changed practice in the field of hepatocellular carcinoma (HCC),  including  development  of  diagnostic criteria and prognostic models and establishment of chemoembolization, SORAFENIB and REGORAFENIB as EFFECTIVE therapy. He founded the International Liver Cancer Association (ILCA) and was its president from 2006 to 2009.
Read more.

Dr. Laurent CASTERA

Board Member

Laurent Castera is currently serving as Secretary General of EASL. He works as Senior Consultant in Hepatology in the Department of Hepatology at the University of Paris-VII (Hôpital Beaujon, Clichy) and is visiting Professor of University College London (Institute of Liver and Digestive Health). His research interests focus on non-invasive methods for liver fibrosis assessment, particularly transient elastography, viral hepatitis and hepatocellular carcinoma.
Read more.

Prof. Tom Hemming KARLSEN

Board Member

Tom Hemming Karlsen is a clinical specialist in internal medicine and gastroenterology working in Oslo, Norway. He is currently serving as Vice-Secretary of EASL. Within the Oslo University Hospital, he is head of research at the Division of Surgery, Inflammatory Medicine and Transplantation and leader of the Norwegian PSC research center at the Department of Transplantation Medicine and Research Institute of Internal Medicine. Clinically, he works as a senior consultant within transplant hepatology at the Section of Gastroenterology at the Department of Transplantation Medicine.
Read more.

Prof. Jeffrey LAZARUS

Board Member

Jeffrey V. Lazarus holds a  position as an affiliated professor at the WHO Collaborating Centre on HIV and Viral Hepatitis at Rigshospitalet, the University of Copenhagen and as an associated researcher at the Barcelona Institute of Global Health (ISGlobal), Hospital Clínic, University of Barcelona. His decade-long career as a health systems, HIV and hepatitis expert at WHO’s Regional Office for Europe was followed by three years at the Global Fund to Fight AIDS, Tuberculosis and Malaria, where he led knowledge translation.
Read more.

Benoit (Dr. iur) MERKT

Board Member

Benoît Merkt, Dr. iur., Attorney at Law, MJur has been a partner of the Swiss law firm Lenz & Staehelin since 2006. He is co-head of Lenz & Staehelin competition law and non-profit/philanthropy practices. He holds a Doctorate in law from the University of Neuchâtel and a Master in European and Comparative Law (MJur) from Oxford University. Benoît Merkt is recognized as a leading competition law expert and a leading practitioner in the law of tax-exempt/non-profit organizations.
Read more.

PROF. ANDREA SIRONI

Board Member

Andrea Sironi is Professor of Banking and Finance at Bocconi University in Milan, where he has been Rector from 2012 to 2016. Since January 2016, he is Chairman of Borsa Italiana SpA and, since October 2016, a member of the Board of Directors of the London Stock Exchange Group. He is currently a member of the Board of Directors of Cassa Depositi e Prestiti SpA and of Cogentech Scarl.
Read more.

Prof. Mark THURSZ

Board Member

Mark Thursz is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and lead clinician for hepatology at St Mary’s Hospital, London. His clinical interests are in viral hepatitis, alcoholic and fatty liver disease.Prof. Thursz is

Prof. Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial. He is chief investigator on the PROLIFICA programme in West Africa.
Read more.

Prof. Hans Heinrich WEDEMEYER

Board Member

Heiner Wedemeyer is a Professor at the Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany. He leads a research group on cellular immunology and clinical virology of viral hepatitis. He is involved in the scientific coordination of the German Network of Competence on Viral Hepatitis (Hep-Net), the German Liver Foundation and the German Hepatitis C Registry. In 2008, he was elected as a Scientific Committee member of the European Association for the Study of the Liver (EASL), and was Secretary General of EASL from 2009 to 2011.
Read more.

Dr. Stefan WIKTOR

Board Member

Stefan Wiktor is a public-health physician with more than twenty-five years’ experience in epidemiologic research and the implementation of public-health programs. Dr Wiktor is Professor of Medicine and Public Health at the University of Washington in Seattle, U.S.

From 2012-2016, Dr. Wiktor was the Team Lead of the World Health Organization’s Global Hepatitis Programme in Geneva, Switzerland which provides guidance and technical assistance to countries to promote the implementation of comprehensive viral hepatitis prevention and control programs.
Read more.